Mirum Pharmaceuticals (MIRM) SVP Howe sells shares to cover RSU taxes

Rhea-AI Filing Summary

Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported equity transactions tied to the vesting of restricted stock units. On January 21, 2026, 1,542 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the scheduled vesting of her award. On January 22, 2026, 926 common shares were sold at an average price of $93.3252 to cover tax withholding obligations related to this vesting. After these transactions, Howe directly held 3,042 shares of common stock and 3,083 restricted stock units, which continue to vest in equal annual installments through the third anniversary of January 21, 2025.

Insider Trade Summary

Net Seller: 926 shares ($86,419)

Net Sell 3 txns

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 926 shs ($86K)

Type	Security	Shares	Price	Value
Sale	Common Stock	926	$93.3252	$86K
Exercise	Restricted Stock Units	1,542	$0.00	--
Exercise	Common Stock	1,542	$0.00	--

Holdings After Transaction: Common Stock — 3,042 shares (Direct); Restricted Stock Units — 3,083 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		M		1,542	A	(1)	3,968	D
Common Stock	01/22/2026		S(2)		926	D	$93.3252	3,042	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/21/2026		M			1,542	(3)	(3)	Common Stock	1,542	$0	3,083	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did MIRM executive Jolanda Howe report?

Jolanda Howe, SVP and global controller of Mirum Pharmaceuticals, reported the vesting and conversion of 1,542 restricted stock units into common shares on January 21, 2026, and the sale of 926 common shares on January 22, 2026 to cover tax withholding obligations.

How many Mirum Pharmaceuticals (MIRM) shares did Jolanda Howe sell and at what price?

On January 22, 2026, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals common stock at an average price of $93.3252 per share to satisfy tax withholding obligations from vested restricted stock units.

How many Mirum Pharmaceuticals (MIRM) shares did Jolanda Howe receive from RSU vesting?

On January 21, 2026, 1,542 restricted stock units held by Jolanda Howe were converted into 1,542 shares of Mirum Pharmaceuticals common stock at an exercise price of $0, reflecting a scheduled vesting event.

What are Jolanda Howes Mirum Pharmaceuticals (MIRM) holdings after these transactions?

Following the reported transactions, Jolanda Howe directly owned 3,042 shares of common stock of Mirum Pharmaceuticals and 3,083 restricted stock units, according to the filing.

Why were some Mirum Pharmaceuticals (MIRM) shares sold by Jolanda Howe?

The filing states that the 926 common shares sold on January 22, 2026 were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

How do Jolanda Howes restricted stock units in MIRM vest over time?

The restricted stock units vest in three equal annual installments. One-third of the shares subject to the RSUs vests on each anniversary of January 21, 2025, so the entire award will be fully vested on the three-year anniversary of that date.